# A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

> **NCT05172856** · PHASE1 · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** IBI321

## Key facts

- **NCT ID:** NCT05172856
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172856, "A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05172856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*